Bone loss in autoimmune chronic active hepatitis on maintenance corticosteroid therapy

Area of Science:

• Hepatology
• Endocrinology
• Bone Metabolism

Background:

• Autoimmune chronic active hepatitis (CAH) is an inflammatory liver disease.
• Corticosteroid therapy is commonly used to manage CAH but is associated with bone loss.

Purpose of the Study:

• To investigate the prevalence of osteoporosis in patients with autoimmune CAH on corticosteroid therapy.
• To assess the impact of corticosteroid treatment on bone mineral density and bone microarchitecture.

Main Methods:

• A cohort of 36 patients with autoimmune CAH on corticosteroid therapy was studied.
• Iliac crest biopsy specimens were analyzed for trabecular bone volume and cortical plate thickness.
• Bone mineral content was measured at the radial metaphysis, diaphysis, and second metacarpal.

Main Results:

• Significant decreases in trabecular bone volume (p=0.005) and cortical plate thickness (p=0.01) were observed in CAH patients.
• Bone mineral content of the radial metaphysis was significantly reduced (p=0.05).
• 47% of patients showed evidence of excessive bone loss; cirrhosis did not exacerbate bone loss.

Conclusions:

• Patients with autoimmune CAH on corticosteroids exhibit significant bone loss, indicating a high frequency of osteoporosis.
• A weak inverse correlation exists between corticosteroid dose/duration and bone parameters.
• Early intervention with calcium and vitamin D is recommended for patients with autoimmune CAH on prednisolone therapy.